Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1988-12-16
1990-10-02
Berch, Mark L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514414, 514418, 514866, 548431, 548468, 548486, C07D20934, C07D20996, C07D491056, A61K 3140
Patent
active
049607855
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
This invention relates to new indolinone derivatives of interest to those in the field of medicinal chemistry and chemotherapy. More particularly, it is concerned with a novel series of oxindole-1-alkanoic acid compounds for the control of certain chronic complications arising from diabetes mellitus (e.g., diabetic cataracts, retinopathy and neuropathy).
BACKGROUND ART
Past attempts to obtain new and better oral antidiabetic agents have, for the most part, involved an endeavor to synthesize new compounds that lower blood sugar levels. More recently, several studies have been conducted concerning the effect of various organic compounds in preventing or arresting certain chronic complications of diabetes, such as diabetic cataracts, neuropathy and retinopathy, etc. For instance, K. Sestanj et al. in U.S. Pat. No. 3,821,383 discloses that certain aldose reductase inhibitors like 1,3-dioxo-1H-benz[d,e]isoquinoline-2(3H)-acetic acid and some closely-related derivatives thereof are useful for these purposes even though they are not known to be hypoglycemic. These compounds function by inhibiting the activity of the enzyme aldose reductase, which is primarily responsible for catalyzing the reduction of aldoses (like glucose and galactose) to the corresponding polyols (such as sorbitol and galactitol) in the human body. In this way, unwanted accumulations of galactitol in the lens of galactosemic subjects and of sorbitol in the lens, retina, peripheral nervous system and kidney of diabetic subjects are prevented or reduced. As a result, these compounds control certain chronic diabetic complications, including those of an ocular nature, since it is already known in the art that the presence of polyols in the lens of the eye leads to cataract formation and concomitant loss of lens clarity.
DISCLOSURE OF THE INVENTION
The present invention relates to novel oxindole-1-alkanoic acid compounds useful as aldose reductase inhibitors for the control of certain chronic complications arising in a diabetic subject. More specifically, the novel compounds of this invention are selected from the group consisting of 3-substituted 2-oxo-indoline-1-alkanoic acids of the formula: ##STR2## and the C.sub.1 -C.sub.6 alkyl esters and primary amide derivatives thereof, and the base salts of said acids with pharmacologically acceptable cations, wherein X is hydrogen and X.sup.1 is hydrogen, hydroxy, fluorine, chlorine, bromine, C.sub.1 -C.sub.4 alkyl or C.sub.1 -C.sub.4 alkoxy; or X and X.sup.1, when taken separately, are each chlorine, C.sub.1 -C.sub.4 alkyl or C.sub.1 -C.sub.4 alkoxy, and when taken together are --OCH.sub.2 (CH.sub.2).sub.n O-- at the 4,5-, 5,6- or 6,7-positions of the molecule wherein n is zero or one; R.sub.1 is hydrogen or methyl; R.sub.2 is hydrogen, C.sub.1 -C.sub.4 alkyl or phenylalkyl having up to three carbon atoms in the alkyl moiety wherein said phenylalkyl is optionally substituted with up to two chlorine substituents on the phenyl ring; R.sub.3 is naphthylmethyl, furfuryl, thenyl, benzothienylmethyl, benzoxazolylmethyl, benzothiazolylmethyl or phenylalkyl having up to three carbon atoms in the alkyl moiety wherein said phenylalkyl is optionally substituted with up to two identical or non-identical substituents on the phenyl ring, said identical substituents being fluorine, chlorine, bromine, trifluoromethyl, C.sub.1 -C.sub.4 alkyl or C.sub.1 -C.sub.4 alkoxy and said non-identical substituents being chlorine, methyl, methoxy or trifluoromethyl; and Y is hydrogen, fluorine, chlorine, C.sub.1 -C.sub.4 alkyl or C.sub.1 -C.sub. 4 alkoxy. These novel compounds are aldose reductase inhibitors and therefore, possess the ability to reduce or inhibit sorbitol formation in the lens and peripheral nerves of diabetic subjects.
One group of compounds of the present invention of interest is that of formula I wherein X is hydrogen; X.sup.1 is hydrogen, hydroxy, fluorine, chlorine or C.sub.1 -C.sub.4 alkoxy; X and X.sup.1, when taken separately, are each C.sub.1 -C.sub.4 alkoxy; R.sub.1 is hydrogen or
REFERENCES:
patent: 3821383 (1974-06-01), Sestanj et al.
patent: 4053613 (1977-10-01), Rovnyak
patent: 4209527 (1980-06-01), Sarges
Howard et al., Chem. Abs 109, 6408e.
Howard, Jr. Harry R.
Sarges Reinhard
Berch Mark L.
Ginsburg Paul H.
Pfizer Inc.
Richardson Peter C.
LandOfFree
Indolinone derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Indolinone derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indolinone derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-292752